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Abstract
Dysregulated cell growth or differentiation due to mis-
expression of developmental critical factors seems to
be a decisive event in oncogenesis. As osteosarcomas
are histologically defined by malignant osteoblasts pro-
ducing an osteoid component, we prospected in pe-
diatric osteosarcomas treated with OS94 protocol the
genomic status of several genes implied in ossification
processes. In 91 osteosarcoma cases, we focused on
the analysis of the fibroblast growth factor receptors
(FGFRs) TWIST, APC, andMET by allelotyping, real-time
quantitative polymerase chain reaction, gene se-
quencing, and protein polymorphism study. Our study
supports the frequent role of TWIST, APC, and MET as
osteosarcoma markers (50%, 62%, and 50%, respec-
tively). TWIST and MET were mainly found to be de-
leted, and no additional APC mutation was identified.
Surprisingly, FGFRs are abnormal in only < 30%. Most
of these factors and their abnormalities seem to be
linked more or less to one clinical subgroup, but the
most significant correlation is the link of MET, TWIST,
and APC abnormalities to a worse outcome and their
combination within abnormal tumors. A wider cohort
is mandatory to define more robust molecular con-
clusions, but these results are to be considered as the
beginning of a more accurate basis for diagnosis, in
search of targeted therapies, and to further characterize
prognostic markers.
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Introduction
Osteogenesis is a complex and coordinated process involving
several intricate signaling pathways, as well as many transcrip-
tion factors. In the 10 past years, the understanding of skeleto-
genesis has made tremendous advances due to progress in
genetic abnormality diagnoses, mice skeletogenesis studies,
and cultured osteoblast or chondroblast models. Bone differ-
entiation occurs both by intramembranous ossification, which
concerns flat bones of the skull and the lateral part of clavicles,
and by endochondral ossification, which concerns the entire
appendicular and axial skeleton [1,2]. Intramembranous ossi-
fication is characterized initially by the local proliferation of
mesenchymal cells, followed by osteoblast differentiation and
local osteogenesis [3,4]. As a more complex process, endo-
chondral ossification needs initially calcified cartilage cores as
rigid scaffold, followed by a vascularization step of this cartilage
structure and ended by a process of cartilage resorption con-
comitantly to bone production [5,6]. Skeletal elements derive
mainly in the head from neural crests; in limbs, they originate
from lateral plate mesoderm, whereas axial skeleton is formed
from somites [2].
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Disorders caused by mutations in organogenesis are
expected to affect skeletal elements in a generalized fashion,
whereas mutations in early patterning genes might target
only specific elements. Thus, mutations in TWIST, MSX2,
and FGFR1–FGFR3 genes alter more specifically the dy-
namics of the ossification of cranial sutures [3,4,7], whereas
SOX9, bone morphogenetic proteins (BMPs), fibroblast
growth factors (especially FGF2), FGFR3, PTHrP and its
receptor (PPR), Indian HedgeHog (IHH ), and vascular en-
dothelial growth factor (VEGF ) are some of the genes acting
in multistep long bone development [8–12]. Factors such as
Cbfa1 or Fgf2 are known to have a role in both processes
[13]. FGF2 has been described to upregulate Twist expres-
sion during the mesenchymal proliferation of intramembra-
nous ossification [3,4], but it also interacts with Hgf and its
receptor Met, promoting chondrocyte differentiation and
seemingly increasing osteoblast proliferation rate through
this pathway, during endochondral osteogenesis [14]. One of
the other common markers is Fgfr3, acting at the osteogenic
front of intramembranous process [4] and also playing a role
in preformed cartilage [9]. The other example is the canonical
Wnt–b-catenin–APC pathway, which has been recently im-
plicated in osteoblast lineage differentiation in both types of
ossifications [15] and which contributes to repressing chon-
drocyte gene expression during skeletogenesis through
Twist signaling [16]. Most of these factors are upregulated
or downregulated at different check points of normal devel-
opment to act through a signaling network of dorsal–ventral
specification andmesoderm determination. For example, up-
regulation of Twist is involved in mesoderm cell proliferation,
whereas downregulation of this protein implies osteoblastic
differentiation [1–3].
These osteogenesis signaling pathways are especially
active during embryogenesis and postnatal bone develop-
ment, but their aberrant activation or suppression can lead
also to development of cancers in differentiated tissues. For
example, fibroblast growth factor receptors (FGFRs) [17–
21], as well as TWIST [22–24] or canonical Wnt signaling
that has been well studied in colon carcinoma multistep
oncogenesis [25], had been frequently described as progres-
sion markers in several cancers. Some of these biomarkers,
such as the Twist or the Wnt–b-catenin–APC pathway, are
also known to have a high rate of proliferative effect on
cancer cells with inhibition of apoptotic signals [23,25]. In
high-grade osteosarcoma characterized by the presence of
malignant osteoblasts and the production of osteoid com-
ponent, it could then be hypothesized that such markers
could play a role in multistep tumorigenesis. As concerns
specifically this malignant bone tumor, only a few of these
markers, such as BMPs, FGFR4, PTHrP, MET, or TWIST,
had been proven to be involved [20,21,26–30]. In addition,
the recent development of biphosphonate, particularly tar-
geting PTHrP in osteosarcomas and based on mice model
and in vitro results [31–33], confirmed experimentally the
interest of using new treatments targeting ossification func-
tions in this cancer.
Therefore, understanding fundamental and develop-
mental ossification processes will probably help to unravel
bone cancer oncogenesis as it will pinpoint pathways whose
alterations contribute to malignant bone tumor onset and
progression. Furthermore, identifying new marker genes
with disordered expression in cancer might be a putative
target for new therapeutic agents.
Then, to gain insight into ossification pathways in bone
cancers, our work focused previously on three markers,
namely, APC, MET, and TWIST genes and loci in a clini-
cally well-known pediatric population of 91 high-grade osteo-
sarcomas [29,30]. These previous studies showed striking
results correlating most of these markers to a worse outcome
or to poor response to chemotherapy. They also showed a
significant correlation between deletion at TWIST and APC
region rearrangements [30]. Based on these promising re-
sults and because of close interactions in both ossification
processes, the status of FGFR1–FGFR4 genes was also
analyzed at DNA level. Then, the first step of this screening
was performed by using microsatellites surrounding MET,
APC, and TWIST genes to confirm the high percentage of
these loci abnormalities found in our previous work. Com-
plementary real-time quantitative polymerase chain reac-
tion (QPCR) targeting MET, TWIST, and FGFR (FGFR1–
FGFR3) genes was performed concomitantly to the se-
quencing of an APC mutation cluster region to understand
the role and alterations of these targeted genes. As one
specific single nucleotide polymorphism (SNP) of FGFR4
gene (G!A), resulting in Gly388Arg substitution [19,20,27,
34], was described as a marker of progression and invasion
in several cancers, we investigated both the genotype status
of our cohort on codon 388 and the copy number of FGFR4
by QPCR. All these molecular results were finally correlated
with clinical and histologic features characterizing this homo-
geneous pediatric population.
Methods
Population, Tumor Banking, and DNA Isolation
Ninety-one pediatric primary high-grade osteosarcomas,
treated homogeneously with OS94 protocol and followed
from November 1994 to June 2006, were included in this
molecular study. The entire study was performed in accor-
dance with the Declaration of Helsinki. The clinical and
histologic characteristics of this population are detailed in
Table 1, and most of them were used for statistical correla-
tions. Most of these patient data had been already described
in our previous works and recently updated [29,30].
Frozen tumor biopsies were collected from each child
at diagnosis, before any treatment. They were stored at
80jC. Because they were dedicated mainly for histologic
diagnosis, only small tumor samples were obtained, allowing
only assessable DNA extraction for these 91 patients. Con-
trol tissue was also obtained from peripheral blood and
conserved on Whatman paper at room temperature. Tumor
and blood paired DNA were purified as already described
in previous publications [29,30,35]. Tumor and blood DNA
concentrations, quantified by fluorometry, ranged from 50 to
400 ng/ml and from 1 to 10 ng/ml, respectively.
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Allelotyping of 5q21, 7p21, and 7q31 Loci
These 91 paired normal and tumor DNA were investigated
by allelotyping with two microsatellites surrounding the APC
gene in 5q21 (D5S346 and D5S492), four microsatellites sur-
rounding the TWIST gene in 7p21 (centromeric D7S2495
and D7S2559; telomeric D7S1683 and D7S2532), and two
microsatellites surrounding the MET gene in 7q31 (D7S486
and D7S677 ) (see primer description at http://www.ncbi.nlm.
nih.gov/genemap99 and http://www.gdb.org Web sites). As
previously described [29,30], DNA from both paired samples
were amplified by fluorescent PCR, which was performed in
an Omnigen Hybaid Thermocycler (Hybaid Ltd., Ashford, UK)
using the following protocols: 5 minutes at 95jC, 35 cycles
of 1 minute at 95jC, 1 minute at 55jC (D5S346, D5S492,
D7S2495, D7S2559, D7S1683, D7S2532, and D7S677 ) or
53jC (D7S486), and 1 minute at 72jC, followed by 5 min-
utes at 72jC. PCR products, after separation with denaturing
urea gel on a sequencer (Amersham Pharmacia Biotech,
Uppsala, Sweden), were directly detected and quantified us-
ing an Alfwin Fragment Analyzer software package (Amersham
Pharmacia Biotech, Uppsala, Sweden). In the last samples,
allelotyping was performed using the automated 3100 Applied
Biosystems (Foster City, CA) combining microsatellites in
multiplex PCRs. This highly reproducible and sensitive tech-
nique is devoted to detecting two genomic abnormalities: mi-
crosatellite instability (MSI) in case of the presence of additional
peaks in tumor samples compared to blood DNA, and allelic
imbalance (AI) characterized by the modification of the allele
ratio in tumor DNA linked to chromosome instability. MSI is
the witness of a mismatch repair defect or RER phenotype,
whereas AI detects both locus deletion and locus amplification
without precision on the real state of the locus. The intensity of
AI is calculated as follows: AI percentage = absolute value[(Bb/
Ba)  (Tb/Ta)  100/(Bb/Ba)], where Ba and Bb represent the
height of two alleles in control blood, and Ta and Tb represent
the height of two alleles in the tumor. The significant cutoff of
allelic variation was set above 20% [35]. Each result was con-
firmed by a duplicate PCR.
Real-Time QPCR of MET, TWIST, and FGFR1–FGFR4
Six genes (MET, TWIST, FGFR1, FGFR2, FGFR3, and
FGFR4) were quantified by QPCR using SYBR Green I dye
(Roche Molecular Biochemicals, Mannheim, Germany) with
Light Cycler technology (Roche Molecular Biochemicals).
Primer sequences were chosen to target introns of each spe-
cific gene and are summarized in Table 2. The two internal
control genes DCK and APP, localized at loci 4q13.3–21.1
and 21q21, respectively, were those used on TWIST in the
same tumor collection in our previous work [30]. The thermal
cycle conditions for the six target and two reference genes
were exactly the same as previously described [30]. For each
experiment, in addition to tumor DNA, a calibrator sample, a
normal control DNA, and a negative control were amplified.
QPCR was performed in duplicate for tumor samples. Result
Table 1. Data for Patients (N = 91) Included in This Molecular Study.
Characteristics Values
Age in years
Mean (range) 12.9 (4–20)
Median 13
Sex
Female 36
Male 55
Localization
Femur 51
Tibia 17
Fibula 2
Talus 1
Humerus 12
Cubitus 2
Pelvis 3
Mandible 1
Metastasis at diagnosis 14
Histologic response
GR 46
PR 41
Unknown 4
Histologic subtypes
Osteoblastic 53
Chondroblastic 10
Fibroblastic 8
Others 4
Unknown 16
Survival
Alive 69
Dead 22 (9 metastatic patients)
OS in months [median (range)] 77 (6–134)
EFS in months (median) 60
Table 2. Real-Time QPCR Primers and Cutoffs Used for the Whole Population.
Genes Forward Primers Reverse Primers Normal Cutoffs Between
MET 5V-CATGCCGACAAGTGCAGTA-3V 5V-CCTAATCTGCAAAGGCCAAAG-3V MET/APP 0.70 and 1.30
MET/DCK 0.60 and 1.40
TWIST 5V-CCTCGGACAAGCTGAGCAAGAT-3V 5V-CCCCACGTCGCCGCGCCAGGAATG-3V TWIST/APP 0.5 and 1.5
TWIST/DCK 0.5 and 1.5
FGFR1 5V-CTTGCCATGGTTCTTCTCCCT-3V 5V-AGGGGCGAGGTCATCACTGC-3V FGFR1/APP 0.5 and 1.5
FGFR1/DCK 0.5 and 1.5
FGFR2 5-CTTGCCTTGAGAATGGTCGTC-3V 5V-AGTCTGGGGAAGCTGTAATCT-3V FGFR2/APP 0.6 and 1.4
FGFR2/DCK 0.5 and 1.5
FGFR3 5V-ACTCACTGGCGTTACTGACT-3V 5V-GAGGATGCCTGCATACACAC-3V FGFR3/APP 0.5 and 1.5
FGFR3/DCK 0.4 and 1.6
FGFR4 5V-TACAGCTTCCTCCGTGTGTG-3V 5V-GCGTACAGGATGATGTCCGT-3V FGFR4/APP 0.5 and 1.5
FGFR4/DCK 0.6 and 1.4
APP 5V-TCAGGTTGACGCCGCTGT-3 5V-ACCCCAGAGGAGCGCCACCTG-3V
DCK 5V-GCCGCCACAAGACTAAGGAAT-3V 5V-AGCTGCCCGTCTTTCTCAGCCAGC-3V
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analyses, using the Light Cycler software version 3.5 (Roche
Molecular Biochemicals), were based on the following rela-
tive calculation:
2  ½ðCP target  CP referenceÞsample  ðCP target  CP referenceÞcalibrator:
CP is the number of cycles for which a fluorescent product
could be measured just above a fluorescent noisy back-
ground. For each couple of target/reference genes, a cohort
of 20 normal samples was investigated to determine the
confidence interval and standard deviations of calculated
ratios. Established normal cutoffs are detailed in Table 2.
PCR Restriction Fragment Length Polymorphism
Analysis of FGFR4
This analysis is based on the detection of SNP variant in
codon 388 of the FGFR4 gene (located in exon 9). Exon 9
of FGFR4 was amplified by PCR using the following primer
set: forward primer 5V-GACCGCAGCAGCGCCCGAGGCC-
AG-3V and reverse primer 5V-AGAGGGAAGCGGGAGAGC-
TTCTGC-3V [20]. The PCR protocol was as follows: a
denaturation step of 94jC for 5 minutes, 35 cycles of 94jC
for 1 minute, 64jC for 1 minute, and 72jC for 1 minute, and
a final extension step of 72jC for 10 minutes. Then, these
PCR products were prepared for digestion with the restric-
tion enzyme BstNI (New England Biolaboratories, Beverly,
MA) and separated with a 4% agarose gel containing ethid-
ium bromide. Electrophoresis allowed us to distinguish be-
tween fragment lengths corresponding to Gly allele at codon
388 (109 bp) and fragment lengths corresponding to Arg
allele (fragments of 80 and 29 bp). Direct sequencing, using
a 3100 automated ABI sequencer (Applied Biosystems),
was also performed to confirm the genotype on PCR prod-
ucts in a majority of cases.
APC Mutation Analysis
PCR amplification of the APC mutation cluster region
(codons 1286–1513) was performed on tumor samples using
five couples of sense and antisense primers, localized from
codons 1200 to 1700 and summarized in Table 3. Purified
PCR fragments were then directly sequenced in both direc-
tions using the BigDye sequencing kit and a 3100 automated
ABI sequencer following the manufacturer’s instructions
(Applied Biosystems, Foster City, CA). In each mutated sam-
ple, a duplicate experiment will be required to confirm the
mutation in two independent amplification products of the
same sample.
Statistical Analysis
The association with clinical and histologic parameters de-
scribed in Table 1 was examined using Pearson’s chi-square
test. Survival curves and correlations with survival outcome for
each molecular marker were performed according to Kaplan-
Meier and used log-rank statistics. Statistical significance was
determined in case of P V .05. All statistical tests were per-
formed using SPSS 11.5 (SPSS, Inc., Chicago, IL).
Results
These 91 children and teenagers are representative of the
whole population treated with OS94 protocol in terms of clini-
cal characteristics and therapeutic results (Table 1) [36], al-
lowing us to consider this tumor collection as one of the
larger homogeneous pediatric osteosarcoma banks. With
data updates, the overall survival (OS) in our population is
77%, and event-free survival (EFS) is 60.2% at 5 years.
Furthermore, response to chemotherapy was statistically sig-
nificant for OS (P = .004) and EFS (P = .06). Thirty-six of the
91 patients included in this molecular study relapsed, and
their median time to relapse was 29 months after diagnosis
(range, 2–102 months).
Ossification Markers Are Significantly Involved
in Pediatric High-Grade Osteosarcomas
As previously published [29,30], loci 7q31, 7p21, and 5q21
are frequently rearranged by allelotyping. As there were only
few discordant results between microsatellites of the same
locus (1 of 91 for MET region; 3 of 76 for TWIST region; and
2 of 91 for APC locus), we could process the following
analysis, and patients considered as informative for these loci
either were heterozygous for both markers (D7S486/D7S677,
D7S2495/D7S2532, and D5S346/D5S492) or presented with
one altered or normal zygosity and with homozygosity at the
second marker. In case of homozygous results for D7S2495/
D7S2532 surrounding the TWIST locus, we did consider,
in addition, the results of two more distant microsatellites
D7S2559 and D7S2532. No MSI was observed, and AI was
found in 52% (37 of 71) for locus 7q31 containing MET, in
46.9% (38 of 81) for locus 7p21 containing TWIST, and in
62.3% (48 of 77) for locus 5q21 containing APC. Looking
closely at the gene status itself by QPCR, MET was normal
in 50% (44 of 88), deleted in 41% (36 of 88), and amplified in
9% (8 of 88) (Table 4). Three patients were not included in
our analysis because two tumor DNA could not be amplified
with MET primers, and the other one was homozygous by
allelotyping and had discordant results with the two control
genes (normal with MET/APP and deleted with MET/DCK ).
Table 3. Primers for APC Gene Sequencing.
Forward Primers Reverse Primers Codons Nucleotides
5V-GTAAGCCAGTCTTTGTGTC-3V 5V-CAGCTGATGACAAAGATGAT-3V 1125–1284 3378–3852
5V-AGACTTATTGTGTAGAAGATAC-3V 5V-ATGGTTCACTCTGAACGGA-3V 1260–1410 3780–4230
5V-TCTGTCAGTTCACTTGATAG-3V 5V-CAT TTGATTCTTTAGGCTGC-3V 1389–1547 4167–4641
5V-ACAGAAAGATGTGGAATTAAG-3V 5V-TTCTCCAGCAGCTAACTCAT-3V 1516–1673 4548–5019
5V-GCTACATCTCTAAGTGATCT-3V 5V-CTTATCATTGAAGTCCTTGG-3V 1654–1826 4962–5478
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TWIST, as already published [30], was normal in 50% (37 of
74), deleted in 36.5% (27 of 74), and amplified in 13.5% (10 of
74) (Table 4). Results by real-time QPCR are matched with
allelotyping in 58 of 71 informative patients for MET, and in
64 of 68 initially informative patients for TWIST. Deletion or
amplification was detected in 4 of 4 discordant results with
TWIST QPCR, and in 6 of 13 discordant results with MET
QPCR, allowing us to conclude for these genes and primers
that the QPCR technique, as previously described, is less
sensitive than allelotyping.
No additional APCmutation in the mutation cluster region
was detected in the normal population by allelotyping, and
neither was there in the rearranged subgroup.
QPCR targeting FGFR1–FGFR4 revealed surprisingly
low rates of abnormalities (20%, 23%, 16%, and 30%,
respectively). When rearranged, FGFR1–FGFR3 are more
often deleted (11%, 21%, and 9%, respectively), whereas
FGFR4 is slightly more often rearranged (30%) and mainly
amplified (24%; 19 of 81 assessable tumors). Complemen-
tary analysis of SNP in FGFR4 at codon 388 revealed Gly/
Gly homozygosity in 54.7% tumors (41 of 75), Gly/Arg het-
erozygosity in 25.3% (19 of 75), and Arg/Arg homozygosity
in 20% (15 of 75).
Statistical analyses combining the results of the different
markers (Figures 1 and 2) showed significant links between
TWIST deletion and loss of heterozygosity (LOH) at the
APC locus (P = .04), as already published [30], between
TWIST and MET deleted subsets (P = .023), and a tendency
between TWIST amplification and FGFR2 deletion (P =
.11). A higher frequency of Arg allele in Fgfr4 protein poly-
morphism was also shown with TWIST amplification. Sur-
prisingly, when cross-table analyses were performed, no
MET amplification was found to be associated with FGFR1,
FGFR2, FGFR3, or FGFR4 amplification, and the highest
rate of normal FGFR populations, especially for FGFR1, was
found in this specific MET subgroup. Furthermore, a MET-
amplified subset was not correlated to TWIST, neither to
the PDGFRA amplification previously described in our popu-
lation [37]. MET amplification was found in only one case
associated with KIT amplification (data previously published
in Entz-Werle et al. [37]). MET deletion was associated
with the highest percentage of APC (5q21) alterations. If we
consider our previously published data on P53, RB, and P16
loci [29], no real differences were observed for TWIST alter-
ations, but in MET alterations, a link between a rearranged
RB1 and MET amplification (P = .06), and between a nor-
mal 9p21 locus containing P16 and this amplified subset
was obvious.
Do These Markers Characterize Clinical Subgroups?
Our analysis also aimed to prospect the potential pre-
dictive value of each marker in different subgroups of pa-
Figure 1. Gene status within TWIST subgroups and statistical combinations. For each gene, we considered the proportion of normal and abnormal subpopulations
in each TWIST subgroup (i.e., normal TWIST, TWIST deletion, and TWIST amplification patients). Black circles underline the main associations.
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tients, namely, localized tumor versus metastatic disease
at diagnosis, no relapse versus relapse(s), the number of
relapses, good responders (GR subgroup) versus poor re-
sponders (PR subgroup) to chemotherapy, alive versus de-
ceased, histopathological subsets (osteoblastic, fibroblastic,
and chondroblastic subtypes), and locations of primary tumor.
The main cross-table statistical analyses are summarized in
Table 4.
Metastatic osteosarcomas (14 children), especially in the
smaller subgroup of deceased metastatic patients (9 children),
are significantly characterized by a higher rate of TWIST ab-
normalities (67% and 75%, P = .05 and .04, respectively) and
a higher range of TWIST amplification. This subgroup also
tends to be linked to APC rearrangement with 89% of 5q21
rearrangements. Neither FGFR2 nor FGFR3 was rearranged
in deceased metastatic patients, and no FGFR deletions were
observed. As concerns FGFR4 polymorphism, the Arg/Arg
388 genotype is significantly absent in the metastatic sub-
group (P = .02).
Interestingly, significant statistical links were observed
in relapsed tumors with TWIST abnormalities (69%, pre-
dominantly deleted; P = .03) and MET abnormalities (70%,
also predominantly deleted; P = .004), but in a higher per-
centage of normal FGFR3 (94%; P = .08) and FGFR4 (83%;
P = .05) genes. In case of abnormalities in these genes,
they are mainly deleted, and no case of amplified FGFR3
was found in the relapse population. The number of relapses
(among 36 relapses, 4 patients relapsed twice) did not mat-
ter to molecular profiles. Considering the response to chemo-
therapy, no significant statistical data distinguishing the GR
subgroup from the PR subgroup were found. The only notice-
able result is the increase in TWIST (56% vs 46%) and APC
(71% vs 58%) abnormalities, normal FGFR3 gene percent-
age (89% vs 79%), and absence of amplification cases at
FGFR2 in the GR subgroup. Comparing molecular profiles
between still-alive patients and deceased children, statistically
significant trends link a high frequency of TWIST and MET
deletions (P = .01 and P = .03), a more frequent APC re-
arrangement (P = .03), and a normal FGFR3 gene (P = .07) to
the deceased population. Due to the small size of the fibro-
blastic and chondroblastic histologic subgroups, the following
observations might not be statistically significant. However,
we observed in chondroblastic osteosarcomas, known to be
more aggressive tumors [36], that the FGFR1 and FGFR3
genes are perfectly normal, that there is no FGFR2 amplifi-
cation or FGFR4 deletion, and that MET is mainly amplified.
The fibroblastic subset had also noticeable higher frequen-
cies of FGFR1 and FGFR3 gene abnormalities and MET
gene abnormality. Finally, considering tumor locations, 12 hu-
merus osteosarcomas are significantly characterized by
TWIST deletion (seven deleted tumors of eight rearranged
tumors) (P = .01), whereas among 58 lower-limb osteosar-
comas, 34 of 58 were normal, 16 of 58 had TWIST deletion,
and 8 of 58 presented TWIST amplification.
The Prognostic Significance of Differentiating Factors
APC, TWIST, and MET remain as prognostic markers in
pediatric osteosarcoma biopsies, as already published
[29,30]. Indeed, TWIST deletion and amplification are signif-
icantly linked to a worse outcome (P = .026 for EFS; P = .019
Figure 2. Gene status within MET subgroups. A combination ofMET subpopulations (normal MET gene, MET deletion, and MET amplification) was made, and the
percentages of normal and altered populations for each gene are given in each graph. Black circles underline the main associations.
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for OS) (Figures 3A and 4A). MET abnormalities are also
significant witnesses of poor EFS, especially MET amplifi-
cation (P = .015; Figure 3B), and tend to be linked to a worse
OS (P = .10; Figure 4B), whereas APC rearrangement tends
only to be correlated to a worse EFS (P = .15; Figure 3C)
and is correlated to a worse OS (P = .035; Figure 4C). No
significant correlation was established for FGFR genes.
Discussion
Ossification Factors Are Involved in Pediatric
High-Grade Osteosarcomas
That rearrangements in APC, TWIST, and MET genes
are detected in around half of the pediatric osteosarcoma
population strongly point toward a role for these ossification
factors in pediatric osteosarcoma oncogenesis. Unlike other
cancers that are mainly described as overexpressing c-Met
or Twist proteins [22–24,38–41], these genes are mostly
deleted in pediatric osteosarcomas (three quarters of abnor-
mal tumors for TWIST and MET presented deletions). Sixty-
two percent of D5S346/D5S492 AI could be also considered
as LOH because we used D5S346 to target the APC locus,
which is relevant to diagnosing APC LOH in colon cancers
[42]. As described above, the decrease in TWIST, APC, and
MET expressions is involved in normal bone production
[1,3,4,15,16,43]. Such observation could explain why gene
deletions in osteosarcoma are detected because undifferen-
tiated and malignant osteoblasts usually produce an osteoid
or a bone component. A significant combination of these
deletions, linking TWIST and MET deletions and APC al-
terations, was observed. This subgroup of TWIST or MET
deletion seems to need additional deleted genes to deregu-
late differentiation to obtain a malignant osteoblast status.
However, TWIST or MET amplification, described as a pro-
liferative cancer factor [22–24], does not need the upregu-
lation of another biomarker to allow osteoblast proliferation
(Figures 1 and 2). The links between this combination of
TWIST, MET, and APC genes seems to be widely explained
through interactions during normal ossification [15,16,43]. In
addition, the decrease in APC and MET expression is spe-
cifically dedicated to endochondral ossification to decrease
chondrocyte component and explains the slight increase in
MET-amplified tumors in our chondroblastic subpopulation
[4,43]. Furthermore, the higher number of TWIST-amplified
chondroblastic tumors might be also explained by the role of
TWIST-increased expression during the intramembranous
ossification process [3,4]. All these rearrangements suggest
a greater role in ‘‘osteogenic’’ profile rather than a role in
progression phenotype, as described by Patane et al. [44]
for c-Met.
In contrast, FGFR1–FGFR4, although documented as
implied in bone growth and/or differentiation, appear only to
be rearranged in about 16% to 30% of osteosarcomas. Both
deletion and amplification are found in these pediatric oste-
osarcomas (FGFR1, FGFR2, and FGFR3 are mainly deleted,
and FGFR4 is amplified) and have also been described
in several adult cancers. For example, Fgfr3 protein is
Figure 3. EFS correlations considering TWIST (A), MET (B), and APC (C)
molecular abnormalities. A statistical correlation for TWIST and MET analy-
ses is found between a worse outcome and rearranged populations, and only
a tendency for APC study.
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overexpressed in hepatocarcinoma [45], whereas the expres-
sion is lost in higher grades and stages of bladder cancers
[46]. Loss of FGFR2 has already been described in osteosar-
comas [21] and brain tumors [47], whereas Fgfr4 protein has
been mainly overexpressed in adult cancers [48]. As less
rearranged genes, FGFRs do not appear as major specific
markers in this pathology. However, FGFRs, which are in-
volved in late bone differentiation [1,2,4], seem to modulate
osteosarcoma oncogenesis, in addition to the main combina-
tion of MET, TWIST, and APC alterations. Indeed, FGFR2
deletion is significantly associated with a TWIST-amplified
subgroup, whereas the absence of alterations in FGFR1–
FGFR3 is frequently observed in the MET-amplified subset
(Figures 1 and 2). As described in calvarial formation, Twist
upregulation and Fgfr2 downregulation are concomitantly
observed [1,4–6]. Considering the FGFR results in Table 4,
no alterations could be associated with an aggressive subtype
of pediatric osteosarcoma. From the point of view of the
osteogenesis process, no statistically significant correlations
for FGFR genes and histologic subgroups could be found.
However, hyperactivation of these receptors was usually
involved during normal bone production of endochondral
ossification and fusion of cranial sutures [1,2], and such
observation could explain the absence of any FGFR1–
FGFR3 amplifications in chondroblastic histologic subtypes
(Table 4).
Ossification Markers, Progression Factors, and/or
Survival Biomarkers
Multiple progression factors, which have been previously
described in other cancers, were analyzed in this study [19,
20,22,23] as TWIST, MET, and APC genes or Fgfr4 pro-
tein polymorphism. Most of them are frequently altered in our
homogeneously treated population of pediatric osteosar-
comas. Concerning FGFR4 genotyping, different percent-
ages (compared to the study of Morimoto et al. [27] on
bone tumors and soft-tissue sarcomas) were shown. In our
population (Table 4), most of the tumors (54.7%) are char-
acterized by a Gly/Gly FGFR4 genotype, whereas in the
bone tumor subgroup of Morimoto et al., which combined
pediatric and adult patients and multiple types of bone malig-
nancies, most of them showed an Arg/Gly FGFR4 genotype
(49%). If we compare our results to the published control
series by Bange et al. [20], Morimoto et al. [27], orWang et al.
[48], our cohort seems to be quite different, with a higher fre-
quency of Arg/Arg FGFR4 genotype (19.7%), usually linked
to an increased mobility in mammary tumor cell lines [20],
and a lower subgroup of Arg/Gly FGFR4 genotype (25.8%),
usually linked to early metastasis in colon cancers [24].
Looking closely at our statistical analyses, significant gene
correlations seem to characterize patients who were diag-
nosed initially with a more agressive disease (metastatic
patients) and those who progressed after diagnosis (tumor
relapses). First of all, one marker is common to both patient
subgroups: TWIST alteration. We observed predominantly
deletions in relapses and deletion or amplification in meta-
static populations. Considering our results, which are summa-
rized in Table 4, the molecular profile of an initial metastatic
osteosarcoma could be an abnormal TWIST gene with a nor-
mal FGFR2 gene (P = .07) and no Arg/Arg FGFR4 genotype
(P = .02), modulated toward a worse outcome by an APC
Figure 4. OS correlations for TWIST (A), MET (B), and APC (C) molecular
abnormalities. A significant correlation is validated between TWIST and APC
alterations and a worse OS, and only a tendency is obtained for both MET
deletion and amplification.
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alteration (P = .07). During relapse, another molecular profile
combining predominant TWIST (P = .03) and MET deletions
(P = .004) and normal FGFR3 and FGFR4 genes (P = .08 and
P = .05, respectively) seems to be highlighted. Among these
markers, abnormal APC and MET genes are probably the
differential factor witnesses of initial invasiveness versus later
progression. Surprisingly, but concordant with previous con-
clusions [27], FGFR4 genotype at codon 388 had no impact
on late progression but seemed to have a role in initial meta-
static disease.
The major altered genes TWIST,MET, and APC and their
combination are also found to be significantly linked to a
worse outcome, as exemplified by statistics in alive and de-
ceased subpopulations and survival analyses. Indeed, some
of these factors are involved in patient outcome and could
be considered as prognostic markers. TWIST deletions and
amplifications seem to have the same worst outcome con-
sequence, whereas MET-amplified tumors are doing worse
than those that are deleted. In fact, patients characterized
by a MET-amplified tumor would only have a 5-year EFS of
28% and a 5-year OS of 53% (Figures 3B and 4B). This last
statement lets us hypothesize that detection of MET ab-
normalities could also subgrade the whole worse outcome
group and select the worst subset of patients. The major
difficulty in both amplified populations is the low number of
tumors, which does not allow us to complete significant
analyses. However, these altered subpopulations for TWIST
and MET genes are characterized by differential molecular
profiles, as shown in Figures 1 and 2. TWIST deletion seems
to be associated with MET deletion and APC alteration,
whereas TWIST amplification is linked to FGFR2 deletion
and Arg/Arg Fgfr4 protein polymorphism. Conversely, MET
amplification seems to be associated with normal FGFRs
and RB1 and with an increase in the number of 9p21 locus
alteration. No clinical factors seem to be associated with
MET amplification, except for increase in chondroblastic his-
tology, which is usually linked to a worse outcome [36].
For FGFR genes, to date, no evident links between out-
come and those genes have been described because of
small abnormal populations. A study on a larger population
would probably be able to define their precise role in osteo-
sarcoma survival.
Could These Factors Be Potential Therapeutic Targets
and/or Used as Routine Biomarkers?
Furthermore,MET and FGFR code for tyrosine kinase re-
ceptors, which are therapeutic targets of recently developed
drugs. Most of these recent treatments inhibit multiple re-
ceptors such as SU006668 or PTK787, targeting, namely,
VEGFR, PDGFR, FGFR, or MET [49,50]. Our findings of
multiple DNA amplifications, leading probably to hyperex-
pression of wild-type receptors, could promote the use of
these new therapeutic strategies. Even though FGFR re-
arrangements are less frequent and amplification is rarer
than deletion, all these findings could help us to refine ac-
curately the subgroup of patients who are able to respond to
these new drugs, targeting the same signaling pathways at
multiple levels. Furthermore, the rapid, sensitive, and useful
techniques described in this study could be used routinely to
analyze the status of these genes as surrogate biomarkers
at diagnosis on biopsies in pediatric osteosarcomas.
Another therapeutic involvement for these analyses could
be an ability to predict a worse clinical outcome at diagnosis,
allowing us to stratify the high-risk group of pediatric osteo-
sarcoma cases that should be treated by new strategies
to intensify present treatment. Thus, defining molecular
profiles of patients would be a helpful tool to determine
therapeutic strategies that fit each critical patient and to
grade osteosarcomas.
To summarize, our findings further expand knowledge
on the role of ossification factor in homogeneous pediatric
osteosarcomas. Much more than being involved in the onco-
genesis of pediatric osteosarcomas, these factors are also
new witnesses to tumor progression and invasiveness and to
a worse outcome group. Their combination seems to be the
key to further understanding osteosarcoma oncogenesis. To
confirm these interesting data, this molecular analysis should
be performed on a larger prospective group to obtain signifi-
cantly statistical analyses in FGFR gene studies.
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